The Final Note
December 2025
Aaron Gerds, MD
Dr. Gerds shares his final Editor's Corner as Editor-in-Chief of ASH Clinical News, reflecting on his time in the role and offering readers one last challenge.
Skip Nav Destination
Editor's Corner
A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab for Treatment of R/R Follicular Lymphoma or Marginal Zone Lymphoma
December 2025
While outcomes for patients with follicular lymphoma are generally good, better options are still needed for those who relapse. Unfortunately, there are fewer options for patients with marginal zone lymphoma.
Pulling Back the Curtain: Robert S. Negrin, MD
December 2025
Dr. Negrin, the incoming 2026 American Society of Hematology (ASH) president, talks about his career inspiration, passion for helping others, and leadership goals for the year ahead.
ATRA-ATO Combination Therapy Improves Efficacy for Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia Over Standard of Care
December 2025
The chemotherapy-free combination of arsenic trioxide (ATO), all-trans retinoic acid (ATRA) plus low-dose idarubicin (ATRA-ATO) demonstrated a significantly higher two-year event-free survival and significantly lower risk of molecular relapse compared with the standard of care.
